Drug analysis: Entresto

  • ID: 4462146
  • Drug Pipelines
  • 21 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Entresto is a first-in-class angiotensin receptor/neprilysin inhibitor consisting of valsartan and sacubitril. Valsartan is an angiotensin receptor blocker (ARB) that competes with angiotensin II for binding to the AT1 receptor, while sacubitril is a prodrug that inhibits neprilysin, an enzyme responsible for the breakdown of several vasoactive peptides. The combined action of both molecules attenuates vasoconstriction and sodium retention, helping to improve the underlying pathology of chronic heart failure.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Entresto: Chronic heart failure (CHF)

List of Figures
Figure 1: Entresto for chronic heart failure - SWOT analysis
Figure 2: Drug assessment summary of Entresto for chronic heart failure
Figure 3: Drug assessment summary of Entresto for chronic heart failure
Figure 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Entresto drug profile
Table 2: Entresto Phase III data in chronic heart failure
Table 3: Ongoing pivotal trials for Entresto in chronic heart failure
Table 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll